

What can an adult neurologist do for you?

A/Prof Lauren Sanders | Neurologist

MBBS GradDipIntlHealth PhD FRACP GDipClinEd St Vincent's Hospital Melbourne & University of Melbourne



Disclosures

- Stroke Fellowship 2009 joint funding Boehringer-Ingelheim and Stroke Unit Monash Medical Centre
- PhD supported by NHMRC scholarship
- **Merck Serono Neurosciences Grant**
- Speaker Fees UCB, Bayer, Pfeizer, BMS, Abbott, Boehringer-Ingelheim
- **Education grant Novartis**
- Advisory boards/working parties Biogen, Roche, Teva, Medtronic, Abbott
- **Medical advisory board Hearts4Heart (NFP)**

Oct 2021

Overview



- Transition to adult neurology
- What does a neurologist do?
- Neurologist role in NMD
- Access to treatments & trials

Questions & Discussion



t 2021 Page 3





TRANSITION TO ADULT NEUROLOGY

Where are we now?




Diseases of childhood → Diseases beginning in childhood

12% Young Adults have chronic condition

90% with childhood conditions reach adulthood

→ transition to adult health system









"It's not as well co-ordinated!"

~ young man with DMD ~





- Often not multidisciplinary
- Rarely nurse/co-ordinator
- Different specialty days (historical)
- Appointment time (in the box)
- DNA not chased



MBS funding

132 (New visit) - \$231.35 133 (review) - \$115.85









Independence & Autonomy

个 Health needs

↑ Physical dependence





ST VINCENT'S HOSPITAL MELBOURNE

Why does transition matter?















WHAT DOES A NEUROLOGIST DO?





Medical school Internship **Basic training** Advanced training Neurologist **Total**: ~ 13-14 years

Paeds training

3-4 months

Young Adult training

3-4 hours

- Fractional/VMO
- Staff Specialist





- Neuromuscular
- Stroke
- Headache
- Epilepsy
- Movement disorders
- Neuroimmunology
- Neurocritical care
- Neurogenetics
- Memory & cognition





Clinical

Research



Education





THE ROLE OF A NEUROLOGIST IN NEUROMUSCULAR CONDITIONS

Footnote to go here Page 13

Interdisciplinary care co-ordination




"multidisciplinary approach....should be coordinated by one of the physicians, generally the neurologist or pediatric neurologist, who is aware of the disease course and potential issues".

Neurologist responsibilities

- Health maintenance
- Maximizing health and functional capacities
- Monitoring of disease progression
- Complications prevention
- Preventive care
- Evidence based management
- Promoting access
- Advocacy
- Advice to other disciplines

- Anaesthetics
- Medications
- Vaccinations







- Correct diagnosis
- Genetic characterisation
 - Prognostication
 - Individualised treatment
 - Clinical trials
- Access to testing
 - Cost
 - Type of testing






ST VINCENT'S HOSPITAL MELBOURNE

- Haven't been routine in adults
- Now recommended
- Physiotherapy shown to slow progression
 - Stretching
 - Positioning
 - Mobility
 - Chest physio


Revised Upper Limb Module for SMA (RULM FOR SMA) Facioscapulohumeral Dystrophy Composite Outcome Measure (FSHD-COM)






MFM self-training DVD

Motor Function Measure
For neuromuscular diseases









Patient reported outcome measures

Table 1
Selected Problems Impacting Health-Related Quality of Life in NMD (n = 1169)

How much difficulty do you have performing the following	Moderate or	Slight	Not a problem
functions?	Severe		
Difficulty with muscle weakness.	72.4%	11.6%	6.0%
Difficulty getting exercise.	66.1%	17.5%	16.3%
Difficulty with fatigue.	70.8%	21.7%	7.6%
Difficulty controlling weight.	36.0%	27.9%	36.2%
Difficulty with sleeping.	36.2%	28.6%	35.1%
Difficulty with muscle contractures.	33.6%	29.9%	36.6%

How much does your health limit you in the following activities?		A little	Not at all
Vigorous activities such as running?	93%	3%	4%
Walking more than a mile?	84%	9%	7%
Walking several blocks?	73%	17%	10%
Walking one block?	54%	27%	18%



McDonald Phys Med Rehabil Clin N Am 2012

Heart Care



- **ECG/Holter**
- **Echocardiogram**
- **Cardiology physician**
- Medications
- Cardiac MRI
- Cardiac devices



























- Lung function tests
- Sleep study
- Respiratory physician
- Proactive airway clearance
- Physiotherapy/ cough assist
- Ventilation support





Bone & Muscle health

- modified bone–muscle cross-talk ⇒ û bone fragility
- Exposure to steroids
- Increased risk osteopenia and fractures
- Yearly DEXA & vitamin D
- Metabolic Bone Clinic & Consideration of medication









- Preventative health
- Immunisations
- Conditions of aging (!)
- Emergency plans
- Surgical management















- Appoint a Medical Treatment Decision Maker
- Chat and Communicate
- Put it on Paper

Patient Story



Dorothy was sick with many health conditions. Her family thought they knew what she wanted, but they weren't 100% sure. Together the family chatted and Dorothy wrote an Advance Care Directive. This he ...

Benefits of ACF



Advance Care Planning reduces stress for your family, clarifies treatments and identifies the legal decision maker for medical staff, gives you peace of mind

When to do ACP



Anyone can do Advance Care Planning.

Read more >

ACP in 3 Steps



Advance Care Planning can be broken down into 3 steps.

Read more >

Read more >





ng can Resources 3 steps.

Read more >

Read more >



Contact Us

Read more >



ACCESS TO TREATMENTS AND TRIALS

Access to treatments



Specialist only medications

Pre-approval access

Specialist facilities

Pipeline drugs

SPINRAZA SOLUTION FOR INJECTION R_x (S4)

Nusinersen (heptadeca Na); clear, colourless, isotonic, preservative free; vial with bromobutyl rubber stopper

Dose: Allow vial contents to warm to room temp; removal of volume of CSF ≡ to dose prior to admin recommended. Admin intrathecal bolus dose by lumbar puncture over 1-3 min. Do not admin into infected, inflamed areas. Loading (initiate as early as poss after diagnosis): 4 doses of 12 mg (5 mL) on days 0, 14, 28, 63; if dose delayed or missed, admin as soon as poss with ≥ 14 day interval. Maintenance: 12 mg (5 mL) every 4 mths; if delayed or missed, admin as soon as poss and continue every 4 mths. Complex, see full PI

Pack 12 mg/5 mL 5 mL [1] (AUSTR282522)

Section 100 (Highly Specialised Drugs) - Public - Authority (MP) (Rp 3)

Approved Indication(s) for Authority: =

Symptomatic Type I, II or IIIa spinal muscular atrophy (SMA)

Treatment Phase: Initial treatment of symptomatic Type I, II or IIIa SMA - Loading doses

Treatment criteria:

Must be treated by a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA; or in consultation with a specialist medical practitioner experienced in the diagnosis and management of SMA associated with a neuromuscular clinic of a recognised hospital in the management of SMA.

Clinical criteria:


The condition must have genetic confirmation of 5q homozygous deletion of the survival motor neuron 1 (SMN1) gene; OR


The condition must have genetic confirmation of deletion of one copy of the SMN1 gene in addition to a pathogenic/likely pathogenic variant in the remaining single copy of the SMN1 gene,

PBS: \$110.000.00



Local interventional studies recruiting adults





FSHD - 0

Myotonic Dystrophy – 0

DMD - 0

CMT - 0


LGMD - 0


OPMD - 0

Myotubular Myopathy – 0

Bethlem Myopathy -

Congenital Muscular Dystrophy -0







https://www.australiannmdregistry.org.au/



register your interest





Day/Month/Year Page 27